CYCC : Summary for Cyclacel Pharmaceuticals, Inc. - Yahoo Finance

U.S. Markets open in 6 hrs 37 mins

Cyclacel Pharmaceuticals, Inc. (CYCC)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
5.44+0.06 (+1.12%)
At close: 4:00PM EST
People also watch
SNSSAEZSCYTXGNVCOPXA
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close5.38
Open5.37
Bid3.50 x 400
Ask5.52 x 500
Day's Range5.30 - 5.48
52 Week Range3.05 - 9.72
Volume25,484
Avg. Volume152,644
Market Cap15.73M
Beta4.66
PE Ratio (TTM)-1.30
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire17 days ago

    Cyclacel Pharmaceuticals to Present at the 19th Annual BIO CEO & Investor Conference

    BERKELEY HEIGHTS, N.J., Feb. 06, 2017-- Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer ...

  • Capital Cubelast month

    ETFs with exposure to Cyclacel Pharmaceuticals, Inc. : January 19, 2017

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETFs with exposure to Cyclacel Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to CYCC-US. Comparing the performance and risk of Cyclacel Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Capital Cube2 months ago

    ETFs with exposure to Cyclacel Pharmaceuticals, Inc. : December 13, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETFs with exposure to Cyclacel Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to CYCC-US. Comparing the performance and risk of Cyclacel Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)